SpliceBio has raised $135M in Series B funding, led by EQT Life Sciences and Sanofi Ventures, to advance its lead gene therapy candidate for Stargardt disease.
SpliceBio has raised $135M in Series B funding, led by EQT Life Sciences and Sanofi Ventures, to advance its lead gene therapy candidate for Stargardt disease.
06/11/25, 7:33 AM
Location
barcelonaMoney raised
$135 million
Industry
biotechnology
Round Type
series b
Investors
Asabys Partners, Novartis Venture Fund, Gilde Healthcare, Ysios Capital, Ucb Ventures, New Enterprise Associates, Roche Venture Fund, Sanofi Ventures, Eqt Life Sciences
SpliceBio, a Barcelona-based clinical-stage genetic medicines company, raised $135M in Series B funding. The round was led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund and existing investors. The funds will support the clinical development of its gene therapy candidate SB-007 for Stargardt disease. Key investors will join the SpliceBio Board of Directors.
Company Info
Location
barcelona, catalonia, spain
Additional Info
SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Our proprietary platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research by our co-founders. The company is backed by UCB Ventures, Ysios Capital, NEA, Gilde Healthcare, Novartis Venture Fund and Asabys Partners.